KBC Group NV Sells 1,139 Shares of Lantheus Holdings, Inc. $LNTH

KBC Group NV lessened its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 38.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,839 shares of the medical equipment provider’s stock after selling 1,139 shares during the quarter. KBC Group NV’s holdings in Lantheus were worth $151,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Cerity Partners LLC lifted its position in Lantheus by 12.7% during the first quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider’s stock valued at $1,143,000 after purchasing an additional 1,323 shares in the last quarter. Signaturefd LLC raised its stake in shares of Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 116 shares during the period. Victory Capital Management Inc. lifted its position in shares of Lantheus by 41.2% during the 1st quarter. Victory Capital Management Inc. now owns 123,067 shares of the medical equipment provider’s stock valued at $12,011,000 after buying an additional 35,937 shares in the last quarter. Teachers Retirement System of The State of Kentucky lifted its position in shares of Lantheus by 2.1% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 33,884 shares of the medical equipment provider’s stock valued at $3,307,000 after buying an additional 695 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its stake in shares of Lantheus by 37.4% during the 1st quarter. KLP Kapitalforvaltning AS now owns 23,123 shares of the medical equipment provider’s stock valued at $2,257,000 after acquiring an additional 6,300 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LNTH has been the topic of several analyst reports. JMP Securities lowered their price target on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. B. Riley lowered their target price on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. TD Cowen lowered their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $61.00 price objective (down previously from $63.00) on shares of Lantheus in a research note on Monday, November 10th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Lantheus presently has an average rating of “Hold” and an average price target of $74.17.

Lantheus Stock Down 1.3%

Shares of LNTH stock opened at $52.79 on Thursday. The company’s fifty day simple moving average is $53.85 and its two-hundred day simple moving average is $65.64. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The stock has a market cap of $3.50 billion, a P/E ratio of 14.04 and a beta of 0.04. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The firm had revenue of $92.51 million during the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. Analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.